Vildagliptin 50 mg +Pioglitazone 15mg

Overview

Z-VIL-P is a fixed-dose combination tablet formulated for the effective management of Type 2 diabetes mellitus It combines Vildagliptin, a DPP-4 inhibitor that enhances insulin release, and pioglitazone, a PPAR-γ agonist that improves insulin sensitivity. This dual approach helps maintain better blood sugar control, improves β-cell activity, and reduces insulin resistance. It is especially useful for patients who are not adequately controlled on single therapy or require multiple drugs to maintain glycemic targets.

Mechanism of Action

• Vildagliptin : Inhibits the DPP-4 enzyme, increasing incretin levels (GLP-1 & GIP), which stimulate insulin secretion and reduce glucagon.

• Pioglitazone : Activates PPAR-γ receptors, enhancing the body’s insulin sensitivity in muscle, fat, and liver cells.

• The combination helps regulate glucose levels both during fasting and after meals.

Indications

• Type 2 Diabetes Mellitus not controlled with diet, exercise, or monotherapy.

• As add-on therapy to metformin for patients not achieving glycemic targets.

• Patients who need combination therapy to reduce pill burden and improve compliance.

Dosage & Administration

• Recommended dose: one tablet daily  (or as advised by physician).

• Can be taken with or without food.

• Regular blood glucose and liver function monitoring are advised.

• Do not discontinue medication abruptly.

Side Effects

Common side effects may include:

• Headache

• Dizziness

• Upper respiratory tract infection

• Weight gain

• Fluid retention or edema

• Fatigue

• Mild hypoglycemia (less common)

Contraindications

• Type 1 diabetes or diabetic ketoacidosis.

• Severe liver impairment.

• Class III or IV heart failure.

• History of bladder cancer.

• Known allergy to Vildagliptin, Pioglitazone, or tablet components.

Precautions

• Monitor liver enzymes during treatment.

• Use cautiously in patients with heart failure due to edema risk.

• May cause weight gain—diet and lifestyle management advised.

• Regular glucose monitoring is essential.

• Elderly patients should be monitored more closely for adverse effects.

Storage Instructions

• Store in a cool, dry place below 30°C.

• Keep away from direct light and moisture.

• Do not remove from blister until use.

• Keep out of children’s reach.

Frequently Asked Questions (FAQs)